Study Finds Concerning Trends Among E-cigarette Users in UK

Sep.30.2024
Study Finds Concerning Trends Among E-cigarette Users in UK
A study of 1,020 e-cigarette users found 39% may buy from unregulated sources, raising concerns about safety.

According to a report by Internewscast on September 29th, a study conducted on 1,020 e-cigarette users found that 39% of them admitted that they may purchase e-cigarettes from unregulated channels that have not been officially safety-checked.


The research results also show that one-third of the respondents believe that their nicotine consumption will increase. However, 22% of people believe that the upcoming law will motivate them to quit their e-cigarette habit.


A study commissioned by the nicotine pouch brand Übbs and retailer Haypp, carried out by OnePoll.com, aimed to respond to the UK government's commitment to achieve a "smoke-free Britain". Earlier this year, the UK government announced legislation that will restrict the sale and use of disposable e-cigarettes by 2025.


According to the survey, since the ban on e-cigarettes was announced, 24% of respondents have attempted to quit using them. 26% of respondents have switched to other alternatives, such as traditional cigarettes (36%), nicotine pouches (26%), and gum (25%).


The study also found that 85% of the respondents had smoked before switching to e-cigarettes, with 52% of them expressing concern about reverting to smoking habits after the ban is implemented.


The spokesperson for the Übbs brand, Steve McGeough, stated that,


Hearing e-cigarette users say they will seriously consider switching to smoking after the ban is implemented is really concerning. Additionally, research also shows that some people may even seek unregulated e-cigarettes, which is very worrying in terms of quality and safety. Our research suggests that while disposable e-cigarettes may be gradually phased out, there are still many safe and regulated alternatives available now or when the ban comes into effect. Nicotine pouches are a popular choice, providing support for the UK's goal to become a smoke-free nation.


The study also found that 73% of e-cigarette users have not tried any e-cigarette alternatives. However, among them, 28% are most likely to try traditional cigarettes, 21% are willing to try gum, and 25% are open to trying nicotine pouches.


Additionally, 30% of respondents are "very aware" of the risks of using unregulated e-cigarettes. The most familiar features of such devices among respondents include the lack of nicotine warning labels (41%) and the absence of emissions testing information (30%). When looking for alternatives, 52% of people prioritize the smell and taste of the product, followed by considerations of safety and quality assurance (50%), and the product's discreteness (33%). 30% of individuals prefer products that are "readily available," while 24% believe that open system e-cigarettes are too complicated.


The study also revealed that running out of battery is the most annoying thing when using e-cigarettes (32%), followed by not being able to use them freely anytime and anywhere (30%). Another major concern is having to leave social gatherings to smoke and missing out on time with friends (23%), and the issue of not being able to use e-cigarettes on airplanes (21%).


Haypp spokesperson Markus Lindbald stated,


From a positive perspective, it is a good phenomenon that before the ban is implemented, so many people are trying to quit e-cigarettes or explore other low-risk alternatives, such as nicotine pouches, instead of turning back to smoking. Based on the nearly smokeless experience in Sweden, nicotine pouches can play an important role in reducing smoking rates and improving public and personal health.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
A federal judge in Texas on Oct. 8 granted a joint request by the FDA and plaintiffs including Altria subsidiaries Helix Innovations and NJOY to stay litigation challenging the agency's 2021 PMTA rule. The court cited FDA's anticipated rulemaking concerning the regulation at issue. FDA announced on Sept. 28 that it intends to reassess the PMTA framework and could initiate new rulemaking to replace it. The parties must file a joint status report within 45 days and every 45 days thereafter. A motion by three Reynolds American companies to intervene remains pending.
Regulations
Oct.10
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
At the 2026 New Approaches Summit in New York, FDA Center for Tobacco Products Director Bret Koplow said the PMTA pathway is “predicated on tobacco harm reduction.” He outlined four CTP priorities: youth prevention, helping adults quit or switch to lower-risk products, improving relative-risk communication, and reducing unauthorized products. Koplow also addressed flavored e-cigarettes, public risk perceptions, industry credibility and efforts to make PMTA reviews more efficient and predictable.
Sep.26
Trump Picks White House Health Policy Aide Heidi Overton to Lead FDA, Pending Senate Confirmation
Trump Picks White House Health Policy Aide Heidi Overton to Lead FDA, Pending Senate Confirmation
U.S. President Donald Trump has chosen White House health policy aide Heidi Overton to lead the Food and Drug Administration, Bloomberg reported, citing a person familiar with the matter. Overton currently works on health policy at the White House and previously held a senior role at the America First Policy Institute. If confirmed by the Senate, she would take over an FDA that has experienced months of senior-level turnover. The agency regulates products representing roughly one-fifth of U.S. consumer spending, including e-cigarettes, drugs, vaccines and much of the food supply.
News
Aug.19
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
A U.S. Government Accountability Office audit found that 131,915 tobacco product applications submitted to the FDA since 2018 remained without a final review as of December 31, 2025, with pending applications waiting an average of 1,266 days. GAO also found FDA lacks the data needed to systematically determine whether scientific reviews meet applicable timelines. HHS agreed to upgrade the agency's tracking systems. At the same time, FDA has begun applying lessons from its nicotine pouch PMTA pilot to e-cigarette reviews, while changes to enforcement policy and electronic submissions are making the specific stage of a PMTA increasingly relevant to market access.
FDA
Oct.03
PMI Global Communications Chief Moira Gilchrist: Why AI Matters More Than Ever in the Smoke-Free Transition
PMI Global Communications Chief Moira Gilchrist: Why AI Matters More Than Ever in the Smoke-Free Transition
Philip Morris International (PMI) Chief Global Communications Officer Moira Gilchrist said artificial intelligence is changing how companies understand audiences, manage owned information channels and communicate business transformation. PMI is using AI-generated audience personas to test messaging while optimizing its corporate website and other owned channels for large language models. As PMI continues its transition from cigarettes toward smoke-free products, Gilchrist said owned data and corporate channels are becoming increasingly important in demonstrating the scale of that transformation.
Aug.26
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24